Eli Lilly CEO Dave Ricks Outlines M&A Strategy Targeting Underserved 'White Spaces' of Science

Eli Lilly CEO Dave Ricks has signaled that the pharmaceutical giant is looking beyond its recent wave of acquisitions to hunt for new growth opportunities in the scientific "white spaces"—fields characterized by high unmet medical needs and limited competition.
Speaking on the sidelines of a recent medical conference, Ricks highlighted areas such as infectious disease, historically underfunded segments of women's health, and complex psychiatric illnesses. This aggressive deal-making stance follows a record-breaking period that has seen Lilly execute roughly 40 deals valued at over $20 billion in 2026 alone, including investments in vaccine developers and psychedelic research.
Rather than engaging in expensive bidding wars for mature assets, Lilly’s strategy focuses on early-stage bets on immature data when target valuations sit closer to $500 million. Backed by surging revenues from its market-leading Mounjaro and Zepbound obesity and diabetes franchise—which propelled total sales to $23 billion in Q2—Lilly is prioritizing reinvestment in human health over share buybacks or dividends as it commands a market capitalization exceeding $1 trillion.